Sort
10,766 grants matching “checkpoint inhibitor”
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia
$714,052Catherine Ju-Ying Wu · Dana-Farber Cancer Inst · R01 · FY2024 · CA
PD-1 blockade with cryoablation and dendritic vaccine to treat lymphoma
$713,488Yi Lin · Mayo Clinic Rochester · R01 · FY2021 · CA
Depleting exosomes to improve responses to immune therapy in HNSCC
$713,327Theresa L. Whiteside · University Of Pittsburgh At Pittsburgh · U01 · FY2022 · DE
Transfer Application - R01 CA223804 - Chemoimmunoprevention of EGFR-Driven Non-Small Cell Lung Cancer
$713,044Ming You · Methodist Hospital Research Institute · R01 · FY2021 · CA
Tissue-based biomarkers of anti-PD-1-based therapy in metastatic renal cell carcinoma
$713,011Toni Choueiri · Dana-Farber Cancer Inst · R01 · FY2025 · CA
DNA Topoisomerases as Target of Action of Anticancer Drugs
$712,998Yves Pommier · Basic Sciences · Z01 · FY2007 · CA
Imaging tumor and T cell responses to metabolic and immune modulation therapy
$712,992Ronald G Blasberg · Sloan-Kettering Inst Can Research · R01 · FY2017 · CA
Imaging tumor and T cell responses to metabolic and immune modulation therapy
$712,992Ronald G Blasberg · Sloan-Kettering Inst Can Research · R01 · FY2018 · CA
Small molecule enhancers of tumor immunity targeting the LPA5 GPCR
$712,726Gabor J Tigyi · University Of Tennessee Health Sci Ctr · R01 · FY2024 · CA
Preclinical development of CM-CX1 for the treatment of ovarian clear cell and renal cell carcinomas
$712,718Joana M Murad · Celdara Medical, Llc · R44 · FY2022 · CA
IGF::OT::IGF R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH)AWARD OF TASK ORDER "OPTIMIZATION AND FURTHER DEVELOPMENT OF MESOTHELIN VACCINE FOR THE PREVENTION OF OVARIAN CANCER"
$712,240Nathalie Scholler · Sri International · N01 · FY2016 · CA
Determinants of toxicity and response to immune checkpoint blockade through integrative profiling of T cell clonal dynamics and plasma cell- free DNA
$711,704Aadel Chaudhuri · Mayo Clinic Rochester · R01 · FY2024 · CA
MDC1: central regulator of estrogen receptor function and therapy response in lobular carcinoma
$711,413Matthew J Sikora · University Of Colorado Denver · R01 · FY2025 · CA
Impact of Circulating Myeloid Cell Clusters on Anti-Tumor Immunity
$711,323Sharon S Evans · Roswell Park Cancer Institute Corp · R01 · FY2021 · CA
Myeloid cell-selective, oligonucleotide-based STAT3 inhibition combined with total marrow and lymphoid irradiation for immunotherapy of acute myeloid leukemia
$711,258Marcin Kortylewski · Beckman Research Institute/City Of Hope · R01 · FY2023 · CA
Immune Checkpoints in Acute Respiratory Distress Syndrome (IC-ARDS)
$710,776Carmen R Mikacenic · Benaroya Research Inst At Virginia Mason · R01 · FY2021 · HL
Preclinical development and clinical monitoring of adoptive immune therapy
$710,207Francis Flomerfelt · Division Of Basic Sciences - Nci · ZIC · FY2022 · CA
Interrogating Mechanisms of Anti-tumor Immunity in Human Subjects and Murine Models of IDH-Mutant Glioma Treated with All-Trans Retinoic Acid and PD-1 Inhibition
$710,142Nduka Mgbechinyere Amankulor · University Of Pennsylvania · R37 · FY2025 · CA
Unraveling the cell divergent roles of Glucocorticoid-Induced TNF-R Related Protein (GITR): A new opportunity to treat atherosclerosis using targeted immunotherapy
$709,869Esther Lutgens · Mayo Clinic Rochester · R01 · FY2025 · HL
Mechanisms of Immune Dysfunction and Morbid Outcome in Response to Shock/Sepsis
$709,642Alfred Ayala · Rhode Island Hospital · R35 · FY2019 · GM
Improving emergency care and outcomes of immune-related adverse events: The immune-related emergency disposition index (IrEDi)
$709,427Cielito C Reyes-Gibby · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
Detection of PD-1 inhibitory signaling and its molecular relays in T cells: Implications for cancer immunotherapy
$709,419Vassiliki A Boussiotis · Beth Israel Deaconess Medical Center · R01 · FY2025 · CA
Immune Response to RBC Antigens
$708,521Krystalyn E Hudson · Columbia University Health Sciences · R01 · FY2025 · HL
Personalizing genetic test results management and outcomes after diagnosis of cancer: the Georgia-California SEER Genelink Study
$708,444Allison W. Kurian · Stanford University · R01 · FY2024 · CA
T cells in the aging brain
$708,203Anne Brunet · Stanford University · R01 · FY2025 · AG